Archive for December, 2008

Internal Medicine News - Zetia

Monday, December 29th, 2008

(ezetimibe, Merck and Schering-Plough)
A cholesterol absorption inhibitor for use as an adjunct to diet for reducing elevated total cholesterol, LDL cholesterol, and apo B levels in patients with primary (heterozygous familial and nonfamilial) hypercholesterolemia, either alone or with an HMG-CoA reductase inhibitor. The first d…

Internal Medicine News - Zetia, with fenofibrate, approved

Thursday, December 25th, 2008

Zetia (ezetimibe) has received an expanded approval in combination with diet and fenofibrate for the reduction of total cholesterol and low-density-lipoprotein cholesterol in patients with mixed hyperlipidemia. In the pivotal study, Zetia 10 mg was administ…

Adverse Event Reporting News - Data about Zetia risks was not fully revealed by Merck and Schering-Plough, evidence suggests

Sunday, December 21st, 2008

Merck and Schering-Plough have conducted several studies of their popular cholesterol medicine Zetia that raise questions about its risks to the liver, but the companies have never published those results, according to a “New York Times” article of Dec. 21.
Partial results of the studies, alluded to in documents on FDA’s website raise questions about whether Zetia can cause liver damage when used long term with other cholesterol drugs…

LegalView Announces the Launch of a New Practice Area on Issues Surrounding Children’s Over-the-Coun

Monday, December 15th, 2008

LegalView announced plans to release a new children’s over-the-counter cough and cold medicine practice area dealing with legal and medical issues surrounding the medication. The practice area is being launched after the U.S. Food and Drug Administration (FDA) released results from a review that found harmful and even deadly side effects exist when treat…

Business Wire - Fitch Places Schering-Plough’s Ratings on Rating Watch Negative

Sunday, December 14th, 2008

CHICAGO — Fitch Ratings has placed Schering-Plough Corp.’s (Schering-Plough) (NYSE:SGP) ratings on Rating Watch Negative. The action applies to approximately $11.98 billion of outstanding debt.
The Rating Watch reflects Fitch’s concern that Schering-Plough will be unable to reduce leverage, total …

LegalView Updates Its Baxter Heparin Information Portal With News of Ongoing United States and China

Friday, December 12th, 2008

Denver, CO - LegalView recently updated its Heparin information portal to include the latest information on the Baxter Heparin recall that may have caused severe allergic reactions and the deaths of more than 80 patients. Investigating the source of contamination has led U.S. officials to a manufacturing plant in China, where over-sulfated chrondroitin sulfate was reportedly chemically altered to simulate Heparin. …

For Widely Used Drug, Question of Usefulness Lingers

Saturday, December 6th, 2008

When the Food and Drug Administration approved a new type of cholesterol-lowering medicine in 2002, it did so on the basis of a handful of clinical trials covering a total of 3,900 patients. None of t…

Be Cautious while Buying Drugs online

Friday, December 5th, 2008

As we know buying anything on internet has become really easier and quicker but the question is that is it ok to buy even very popular drugs without prescription?
Just take an example of a popular drug, Lipitor. Buy Lipitor online is easy. Lipitor (Atorvastatin) is a popular medicine that is widely prescribed to patients in order to prevent strokes and heart attacks by lowering the bodys production of LDL. This is given to lower the patients blood cholesterol l…

Clear and Present Dangers of Cholesterol Lowering Drugs

Tuesday, December 2nd, 2008

You probably know by now that top cholesterol drugs Vytorin and Zetia have been proven to have no benefits, doctors and patients have to rely on older lowering cholesterol drugs such as statins. Regardless of which drugs you take to lower cholesterol, there may be som…